Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00915603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)
Study identification
- NCT ID
- NCT00915603
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Enrollment
- 113 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Everolimus Drug
- Paclitaxel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2009
- Primary completion
- May 31, 2014
- Completion
- Jun 30, 2014
- Last update posted
- Dec 21, 2014
2009 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wilshire Oncology Medical Group | LaVerne | California | 91750 | — |
| Eastern Connecticut Hematology Oncology | Norwich | Connecticut | 06360 | — |
| Aventura Medical Center | Aventura | Florida | 33180 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Mercy Hospital | Portland | Maine | 04101 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Associates | Bethesda | Maryland | 20817 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| South Carolina Oncology Associates, PA | Columbia | South Carolina | 29210 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
| Fairfax Northern Virginia Hem-Onc | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00915603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2014 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00915603 live on ClinicalTrials.gov.